
Supplementary Fig. S4. Grade ≥3 adverse events (AEs) of clinical interest by time to onset from first dose in the first line (A) and relapsed/refractory (B) settings. Presented are adverse events of particular clinical interest identified early during ibrutinib development. The dashed lines represent a 5% rate. No other events of major hemorrhage were reported. Numbers at the end of each bar represent the percentage of patients with AE onset during that time interval after the first dose date.

Α



В **Overall Study** ≤1 Year >1-2 Year >2-3 Year >3-4 Year >4-5 Year >5-6 Year >6-7 Year (n=101)(n=77)(n=63)(n=54)(n=39)(n=28)(n=21)(N=101)Grade ≥3 AEs 2 3 Bleeding 15 14 5 Hypertension Atrial fibrillation Infection 11 **1** 3 2 11 Thrombocytopenia 4 3 Arthralgia Patients (%)